Discussion
Larimar Therapeutics has completed an application asking the U.S. Food and Drug Administration (FDA) to approve nomlabofusp, its experimental protein replacement therapy for Friedreich’s ataxia (FA). Because nomlabofusp had previously earned certain regulatory designations aimed at speeding its development, Larimar was allowed to do a rolling…
